Schering v. E. F. Hutton
Schering announced it was dropping its suit against the brokerage firm because Hutton has sold more than 900,000 shares of Schering stock. The suit, filed in New Jersey Federal Court Dec. 6, charged Hutton with inside trading of Schering-Plough stock based on confidential information provided to Hutton by Schering ("The Pink Sheet" Dec. 16, T&G-6).
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.